Please login to the form below

Not currently logged in
Email:
Password:

PARP inhibitor

This page shows the latest PARP inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

of targeted cancer drugs, along with BTK inhibitor Calquence (acalabrutinib) for B-cell malignancies which picked up its first approval last year. ... cancer. However, AZ has two other targeted drugs – PARP inhibitor Lynparza (olaparib) for breast and

Latest news

  • DNA damage specialists Artios Pharma raises $84m DNA damage specialists Artios Pharma raises $84m

    While many were initially sceptical about the clinical and commercial potential of the first generation DDR drugs, the PARP inhibitor class which Lynparza belongs to, their growing commercial success means confidence ... DDR is an exciting field of

  • China’s BeiGene raises $903m from Hong Kong IPO China’s BeiGene raises $903m from Hong Kong IPO

    cancer (NSCLC), hepatocellular carcinoma, and oesophageal squamous cell carcinoma, the company is developing BTK inhibitor zanubrutinib and pamiparib, a PARP 1/2 inhibitor. ... It’s a potential rival to marketed PARP inhibitors from AstraZeneca

  • New cancer drugs can’t quite plug the revenue hole at AZ New cancer drugs can’t quite plug the revenue hole at AZ

    PARP inhibitor Lynparza’s new approval in breast cancer and shift earlier in the treatment pathway in ovarian cancer drove sales up 124% in the first half to $269m, aided by ... cancer. The MEK inhibitor had previously failed in a late-stage lung

  • AZ and MSD surpass rivals with updated Lynparza data AZ and MSD surpass rivals with updated Lynparza data

    AstraZeneca’s (AZ) and Merck Sharp &Dohme’s (MSD) push for first-line setting for its revamped PARP inhibitor Lynparza (olaparib) has been bolstered by some positive phase III data. ... in the first-line maintenance setting for women with

  • Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more

    Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more. ... ONCOLOGY. Pfizer files PARP inhibitor contender in US and Europe. There may already be three PARP inhibitor cancer drugs on the market, but Pfizer believes there is

More from news
Approximately 1 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... 540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute

  • Deal Watch April 2016 Deal Watch April 2016

    3, 340. Nimbus Apollo (US). Gilead (US). Company acquisition. Phase I Acetyl-CoA Carboxylase (ACC) inhibitor programme for live disease. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for

  • Pharma deals in August 2015 Pharma deals in August 2015

    Looking at another combination, AstraZeneca entered into a clinical trial collaboration this time with durvalumab in combination with Mirati Therapeutics' investigational spectrum-selective histone deacetylase (HDAC) inhibitor, mocetinostat.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... The former is a PARP inhibitor currently under review in both the EU and the US for ovarian cancer, while AZ

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics